Preprint
Early Treatment with Fluvoxamine Among Patients with COVID-19: A Cost-Consequence Model
Abstract
Summary Background Three randomized trials have been conducted indicating a clinical benefit of early treatment with fluvoxamine versus placebo for adults with symptomatic COVID-19. We assessed the cost-consequences associated with the use of this early treatment in outpatient populations. Methods Using results from the three completed trials of fluvoxamine vs. placebo for the treatment of COVID-19, we performed a meta-analysis. We conducted …
Authors
Mills FP; Reis G; Thorlund K; Forrest JI; Guo CM; Boulware DR; Mills EJ; Investigators FTT
DOI
10.1101/2021.12.23.21268352
Preprint server
medRxiv